Illumina News and Research

RSS

New pricing of $19,500 set for Illumina's individual genome sequencing service

Illumina, Inc. today announced a new price of $19,500 for its individual genome sequencing service. In addition, the company announced a price of $14,500 per genome for groups of five or more participants using the same physician. Individuals with serious medical conditions for whom whole-genome sequencing could provide potential direct clinical value will be eligible for special pricing of $9,500 per genome.

From Illumina, Inc. 4 Jun 2010

Illumina commences shipment of new HumanOmni2.5-Quad DNA Analysis BeadChip microarray

Illumina, Inc. today announced that it has begun shipping its new HumanOmni2.5-Quad DNA Analysis BeadChip (Omni2.5). This microarray contains millions of newly discovered genome-wide common and rare variants from the 1,000 Genomes Project (1kGP), selected to maximize its ability to detect new associations.

From Illumina, Inc. 2 Jun 2010

Texas A&M uses pGAP and IBM supercomputing technology to boost tuberculosis research

IBM today announced that Texas A&M University used IBM supercomputing technology to carry out potentially life-saving tuberculosis research at a rate more than four times faster than was previously possible.

2 Jun 2010

Various aspects of consumer genetics to be discussed at 2nd Annual Consumer Genetics Conference

At the 2nd Annual Consumer Genetics Conference taking place in Boston from June 2-4 at the Hynes Convention Center, these issues will be addressed and preeminent leaders from varying areas of expertise will provide perspectives on these crucial topics that are shaping the way we approach clinical medicine and helping to improve patient outcomes.

29 May 2010

Mount Sinai School of Medicine deploys Isilon scale-out NAS for DNA sequencing and analysis workflow

Isilon® Systems today announced that Mount Sinai School of Medicine's Genomics Institute and Department of Genetics and Genomic Sciences has deployed Isilon scale-out NAS as the primary repository for its next-generation DNA sequencing and analysis workflow.

27 May 2010

SiMoA technology measures individual PSA molecules in prostate cancer patients: Nature Biotechnology

Quanterix Corporation, the single molecule diagnostics company focused on developing and commercializing high sensitivity tests, announced the publication of a breakthrough study of the company's proprietary technology that demonstrates an unprecedented sensitivity for measuring a biomarker for prostate cancer recurrence.

24 May 2010

FDA grants Illumina 510(k) clearance for VeraCode Genotyping Test for Factor V and Factor II

Illumina, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance for the VeraCode® Genotyping Test for Factor V (Leiden) and Factor II (Prothrombin).

From Illumina, Inc. 19 May 2010

GATC Biotech to sequence samples from pediatric brain tumors for world's largest cancer research project

GATC Biotech to sequence samples from brain tumors in children for the world's largest cancer research project. The aim of the German PedBrainTumor Consortium within the ICGC is to develop innovative diagnostic methods and treatments in order to be able to provide children with therapies which have fewer side effects in future.

18 May 2010

Series Three of Percepta's Gene Expression Profiling Life Science Dashboard market research report

Percepta Associates Inc. announces the release of Series Three of its Gene Expression Profiling Life Science Dashboard market research report. Unique to the Percepta report, Series Three offers comparisons to the findings of Series One (February 2007) and Series Two (April 2008).

6 May 2010

FDA grants market clearance for Illumina's BeadXpress system for multiplex genetic analysis

Illumina, Inc. today announced that the U.S. Food and Drug Administration has granted 510(k) market clearance for the company's BeadXpress system for multiplex genetic analysis.

From Illumina, Inc. 4 May 2010

A crystal ball into your future health!

Imagine knowing just what diseases you are likely to suffer from in your lifetime thanks to the sequencing of your genes. That is exactly what Professor Stephen Quake knows, because he has had his entire genome sequenced and studied. In fact he was in the news last year as well when he used new technology to sequence his genetic code for less than $50,000.

29 Apr 2010

Illumina announces shipment of HiScanSQ system for research needs

Illumina, Inc. today announced shipment of HiScanSQ, the first instrument to integrate microarray analysis and next-generation sequencing in a modular design that can evolve with changing research needs.

From Illumina, Inc. 27 Apr 2010

NCGR deploys Isilon scale-out NAS to power genome sequencing research services

Isilon Systems today announced that the National Center for Genome Resources has deployed Isilon scale-out NAS to power its full range of next-generation genome sequencing research services. By combining Isilon's X-Series, Backup Accelerator and CommVault's Simpana backup software, NCGR has unified eight Illumina Genome Analyzers onto a highly reliable, central storage resource, accelerating time-to-results and ensuring its research information is secure and accessible 24x7x365.

21 Apr 2010

New web-based service for analyzing, visualizing and managing DNA sequencing data

DNAnexus, Inc. today announced the commercial launch of its web-based service for analyzing, visualizing, and managing next-generation DNA sequencing data. Andreas Sundquist, Ph.D., co-founder and CEO, will introduce the solution publicly for the first time today at the annual Bio-IT World Conference and Expo in Boston, Massachusetts.

20 Apr 2010

Illumina announces first named family DNA sequence

Illumina, Inc. today announced that it has sequenced the DNA of John, Judy, Anne and Paul West, the first publicly named family to have their DNA sequenced to full coverage by the company.

From Illumina, Inc. 17 Apr 2010

Illumina launches VeraCode ADME Core Panel

Illumina, Inc. today announced the launch of its VeraCode ADME Core Panel designed to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most complete representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List.

From Illumina, Inc. 7 Apr 2010

Biotech reports record financial results for 2010 first quarter

Biotech racked up impressive gains for both the month of March and the first quarter of 2010. The Burrill Biotech Select Index posted a 3.7 percent jump in value in March and an 8 percent overall gain for Q1 '10.

2 Apr 2010

Neogen announces acquisition of GeneSeek

Neogen Corporation announced today that it had purchased all the outstanding shares of GeneSeek, Inc., of Lincoln, Neb. GeneSeek is considered the leading commercial agricultural genetics laboratory in the United States.

1 Apr 2010

Ambry Genetics introduces a suite of genetic tests to pinpoint the cause of mental retardation

Ambry Genetics today introduced The Ambry X-Linked Mental Retardation SuperPANEL™, a suite of genetic tests expected to pinpoint the cause of intellectual disability and X-linked mental retardation (XLMR).

24 Mar 2010

Finding right balance between high-throughput sequencing and related bioinformatics analysis

Balancing high-throughput sequencing and related bioinformatics analysis between a research group’s internal efforts and specialized service providers can both speed results to difficult biological questions and provide cost-effective access to the latest technology, says Eureka Genomics (EG). The company’s unique capabilities and services and how they can help in “Finding the Right Balance” will be the topic of discussion at a “Java and Jive” session on Wednesday March 17, 8:15 am at the Now-Generation Sequencing conference being held at the Hilton San Diego Resort in San Diego, CA.

17 Mar 2010